Is Dianthus Therapeutics, Inc. (NASDAQ:DNTH) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Dianthus Therapeutics, Inc. at current levels.
Claseprubart is shaping up as the next-generation complement franchise, with gMG data due to reset how the Street values C1s inhibition.
Where DNTH is headed
By late 2027, Dianthus should own the cleanest shot at unseating Argenx and UCB across the C1s-driven autoimmune spectrum. Claseprubart is engineered with a half-life that supports monthly, and eventually quarterly, subcutaneous dosing. That is the number that matters. Vyvgart's commercial success has proven patients will pay a premium for an antibody-mediated autoimmune drug that works, but weekly infusions are the ceiling on that market, not the floor. If claseprubart lands its generalized myasthenia gravis (gMG) readout with a clean efficacy profile and dosing convenience, Dianthus is not competing for scraps. It is competing for the front line.
Read the full Compass Direction on DNTH
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $112.11).
See the full DNTH analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Dianthus Therapeutics, Inc. (NASDAQ:DNTH) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Dianthus Therapeutics, Inc. at current levels. Claseprubart is shaping up as the next-generation complement franchise, with gMG data due to reset how the Street values C1s inhibition.
What is DNTH's Compass Score?
Dianthus Therapeutics, Inc. scores 88/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for DNTH?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the DNTH page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.